Arcus Biosciences Inc (RCUS) Stock Price, Quote & News

Company Profile

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 694 6200

Website: www.arcusbio.com

Address:

3928 Point Eden Way, Hayward, United States

ridesky Dec. 23 at 5:40 PM

$RCUS This group is scamming many stocks and RCUS is the one.

0 · Reply

MRTunity Dec. 22 at 6:09 PM

$RCUS going to fill that gap back towards $26 this holiday season ?! 🎅 📈

0 · Reply

ACES_ Dec. 20 at 3:22 AM

$RCUS lucky

0 · Reply

Bobes Dec. 19 at 9:40 PM

$RCUS someone is getting a lot of shares via options today

0 · Reply

tradingjunk321 Dec. 17 at 9:07 AM

$RCUS since when does RCUS trade at 4:05AM? News coming?

1 · Reply

Bmdubb Dec. 16 at 5:04 PM

$RCUS flush it.

1 · Reply

ZacksResearch Dec. 15 at 7:25 PM

$RCUS drops 14.4% after halting STAR-221 study for futility. 📉 The domvanalimab-based combo failed to improve overall survival compared to the existing treatment. Despite this, RCUS shares have gained 44.6% year to date, outpacing the industry's 18.2% growth. https://www.zacks.com/stock/news/2804472/rcus-stock-down-on-decision-to-discontinue-gild-partnered-study?cid=sm-stocktwits-2-2804472-body-24916&ADID=SYND_STOCKTWITS_TWEET_2_2804472_BODY_24916

1 · Reply

ZacksResearch Dec. 15 at 6:25 PM

$RCUS hit hard — late-stage setback investors can’t ignore ⚠️ Arcus discontinued the STAR-221 study for futility, dealing a blow to its domvanalimab program partnered with $GILD, and the stock is down on the news. Understand what went wrong and what it means next 👉 https://www.zacks.com/stock/news/2804472/rcus-stock-down-on-decision-to-discontinue-gild-partnered-study?cid=sm-stocktwits-2-2804472-teaser-24915&ADID=SYND_STOCKTWITS_TWEET_2_2804472_TEASER_24915

0 · Reply

BIgkill Dec. 15 at 3:13 PM

$RCUS

1 · Reply

AAUS1 Dec. 14 at 3:58 PM

$RCUS good chance for those who missed 🤣

0 · Reply

Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 9:02 AM EST - 9 days ago

Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221

Dec 12, 2025, 1:35 PM EST - 13 days ago

Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug

Dec 12, 2025, 8:30 AM EST - 14 days ago

Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio

Dec 9, 2025, 6:00 PM EST - 16 days ago

Arcus Biosciences Announces New Employment Inducement Grants

Dec 3, 2025, 2:33 PM EST - 22 days ago

Arcus Biosciences, Inc. (RCUS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 18, 2025, 4:05 PM EST - 5 weeks ago

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Oct 30, 2025, 11:35 PM EDT - 2 months ago

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Oct 30, 2025, 4:01 PM EDT - 2 months ago

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

Oct 28, 2025, 4:05 PM EDT - 2 months ago

Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update

Oct 19, 2025, 7:00 PM EDT - 2 months ago

Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia

Oct 16, 2025, 11:18 AM EDT - 2 months ago

Arcus Biosciences: Refusing To Let The TIGIT Story Die, And Finding Potential Niches In Huge Markets

Oct 12, 2025, 6:05 PM EDT - 2 months ago

Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study

Oct 6, 2025, 11:15 PM EDT - 2 months ago

Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call Transcript

Oct 6, 2025, 2:23 PM EDT - 2 months ago

Why Is Arcus Biosciences Stock Trading Higher On Monday?

Oct 6, 2025, 8:00 AM EDT - 2 months ago

Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event

Sep 10, 2025, 11:59 AM EDT - 3 months ago

Arcus Biosciences, Inc. (RCUS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 5:08 PM EDT - 4 months ago

Arcus Biosciences, Inc. (RCUS) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 2, 2025, 4:05 PM EDT - 4 months ago

Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation

Aug 20, 2025, 4:05 PM EDT - 4 months ago

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

Aug 14, 2025, 8:07 AM EDT - 4 months ago

Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus

UEC

Aug 10, 2025, 9:34 AM EDT - 4 months ago

Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months

Aug 6, 2025, 4:05 PM EDT - 5 months ago

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

Jul 10, 2025, 8:30 AM EDT - 6 months ago

Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer

Jun 1, 2025, 10:45 AM EDT - 7 months ago

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

May 6, 2025, 8:17 PM EDT - 8 months ago

Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:05 PM EDT - 8 months ago

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

Apr 23, 2025, 4:05 PM EDT - 8 months ago

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

Apr 22, 2025, 4:05 PM EDT - 8 months ago

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

Apr 2, 2025, 3:48 PM EDT - 9 months ago

Arcus Biosciences: A High-Risk Speculation With Multiple Large, Near-Term Catalysts

Feb 25, 2025, 4:05 PM EST - 10 months ago

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

Feb 18, 2025, 6:57 AM EST - 11 months ago

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

Feb 18, 2025, 6:52 AM EST - 11 months ago

Arcus Biosciences, Inc. Announces Underwritten Offering of Common Stock

Feb 15, 2025, 3:45 PM EST - 11 months ago

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Feb 10, 2025, 5:00 PM EST - 11 months ago

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

Jan 21, 2025, 4:05 PM EST - 1 year ago

Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

Jan 14, 2025, 10:51 PM EST - 1 year ago

Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025

Jan 13, 2025, 8:00 AM EST - 1 year ago

Arcus: Excellent Pipeline And Collaborations, Cash Runway

Dec 19, 2024, 4:05 PM EST - 1 year ago

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Nov 6, 2024, 11:39 PM EST - 1 year ago

Arcus Biosciences, Inc. (RCUS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:22 PM EST - 1 year ago

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Nov 5, 2024, 9:00 AM EST - 1 year ago

Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer

Oct 30, 2024, 9:00 AM EDT - 1 year ago

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Oct 24, 2024, 7:30 AM EDT - 1 year ago

First Clinical Data for Arcus Biosciences' HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Oct 22, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma

AZN

Sep 23, 2024, 1:53 AM EDT - 1 year ago

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Arcus Biosciences Secures Up to $250 Million Term Loan Facility from Hercules Capital

HTGC

Aug 9, 2024, 5:31 PM EDT - 1 year ago

Arcus Biosciences: Getting Too Cheap To Ignore (Reiterate Buy)

ridesky Dec. 23 at 5:40 PM

$RCUS This group is scamming many stocks and RCUS is the one.

0 · Reply

MRTunity Dec. 22 at 6:09 PM

$RCUS going to fill that gap back towards $26 this holiday season ?! 🎅 📈

0 · Reply

ACES_ Dec. 20 at 3:22 AM

$RCUS lucky

0 · Reply

Bobes Dec. 19 at 9:40 PM

$RCUS someone is getting a lot of shares via options today

0 · Reply

tradingjunk321 Dec. 17 at 9:07 AM

$RCUS since when does RCUS trade at 4:05AM? News coming?

1 · Reply

Bmdubb Dec. 16 at 5:04 PM

$RCUS flush it.

1 · Reply

ZacksResearch Dec. 15 at 7:25 PM

1 · Reply

ZacksResearch Dec. 15 at 6:25 PM

0 · Reply

BIgkill Dec. 15 at 3:13 PM

$RCUS

1 · Reply

AAUS1 Dec. 14 at 3:58 PM

$RCUS good chance for those who missed 🤣

0 · Reply

TabJones24 Dec. 13 at 10:49 PM

$RCUS They are going to shut bed with kidney cancer too Shady

1 · Reply

Bobes Dec. 12 at 9:57 PM

$RCUS maybe gild comes in now at 30. So at 30 its 4.2b but they own 25% so 3.2 plus they get 1b in cash plus the can writeoff their tigit investment. So 2.2b plus the writeoff. And they get the rest of the pipe.

2 · Reply

Bobes Dec. 12 at 9:54 PM

$RCUS todays news was not good but remember we stil have Casdatifan which is in p3. I feel much better about Cas given the p2 data was more robust and because of Belzutifan we know the moa. In addition we can predict the market based on Belzutifan as well. Everyone i spoke to says Casdatifan should be a 2b peak drug which means there is still a lot of value here. We will get data in 26. I also suprised that 3 out the four firms that commented today increased their pt.

0 · Reply

Bmdubb Dec. 12 at 8:09 PM

$RCUS flush it

0 · Reply

JarvisFlow Dec. 12 at 4:49 PM

HC Wainwright & Co. has updated their rating for Arcus Biosciences ( $RCUS ) to Buy with a price target of 32.

0 · Reply

ShKumaresan Dec. 12 at 4:46 PM

$RCUS Why Did Arcus Biosciences Stock Slump 10% Today? https://stocktwits.com/news-articles/markets/equity/why-did-arcus-biosciences-stock-slump-10-percent-today/cLICnrIRE8R

0 · Reply

StocktwitsNews Dec. 12 at 4:45 PM

Why Did Arcus Biosciences Stock Slump 10% Today? $RCUS https://stocktwits.com/news/equity/markets/why-did-arcus-biosciences-stock-slump-10-percent-today/cLICnrIRE8R

0 · Reply

MRTunity Dec. 12 at 3:44 PM

$RCUS here is that consolidating I mentioned 15min ago… be careful here ⚠️ Bearish until or unless back above $24.05 PLUS

1 · Reply

50bps Dec. 12 at 3:31 PM

$RCUS impressive

0 · Reply

MRTunity Dec. 12 at 3:28 PM

$RCUS 🚨 sweet swing ! Bought back $21 on opening gap as posted just sold at $23.94 avg potential double top and don’t want to be greedy - 17% approx SWING in an hour is a WIN‼️ Needs to consolidate I believe now, so technicals intraday cool and buy back again before the bell 🔔 … falls back to $23 ish may buy back again earlier than expected

2 · Reply

www_larval_com Dec. 12 at 2:37 PM

$MIGI 13%[6%] $ABVE 9%[-25%] $BBGI -8%[-1%] $RCUS 7%[-12%] $TLRY -6%[33%] most notable movement within the first minutes of trading.

0 · Reply

MRTunity Dec. 12 at 2:34 PM

@Bobes based on my technicals, market value and charting $21 ISH is where I just bought back my shares sold near $26- GL! $RCUS

0 · Reply

Market Cap	2.50B
Revenue (ttm)	258.00M
Net Income (ttm)	-283.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-109.69%
Debt to Equity Ratio	0.22

Volume	444,800
Avg Vol	1,993,736
Day's Range	N/A - N/A
Shares Out	107.97M
Stochastic %K	76%
Beta	0.75
Analysts	Strong Sell
Price Target	$33.70